GeneFab Appoints Vadim Eristavi as Head of Quality to Bolster Commercial Readiness for Manufacturing of Cell and Gene Therapies
Alameda, CA — January 6, 2025 — GeneFab is pleased to announce the appointment of Vadim Eristavi as its new Vice President of Quality. Bringing over 25 years of extensive experience in the biopharmaceutical industry, Vadim will oversee the Quality Assurance and Quality Control teams at GeneFab, driving the enhancement and expansion of quality operations as the company scales its capabilities in the cell and gene therapy sector.
​
In his new role, Vadim will leverage his considerable clinical and commercial manufacturing experience to develop robust quality programs that are critical for GeneFab's growth trajectory, support the success of our clients' innovative programs, and reinforce our commitment to operational excellence. His proven track record includes establishing phase-appropriate QA/QC capabilities that support development, manufacturing, and clinical studies, ensuring regulatory compliance at all stages of the process.
​
“Vadim's expertise in Quality leadership across large and midsize companies, as well as his experience in CDMO operations, positions GeneFab at the forefront of innovation in the cell and gene therapy space,” stated Philip Lee, Ph.D., CEO of GeneFab. “We are excited to welcome him to our team as we continue to scale our operations and enhance our commercial readiness.”
​
Before joining GeneFab, Vadim served as Vice President of Quality at a midsize CDMO, where he led key quality initiatives to support early- and late-phase clinical manufacturing. In his previous role as Global External Quality Emerging Markets Lead at Roche/Genentech, he played a pivotal role in product launches, technology and method transfers, and in-licensing activities across Roche's global commercial supplier network. Following his tenure at Roche, Vadim joined Miltenyi Biotech, where he successfully established the Quality Control department and qualified a new GMP QC laboratory to support both early- and late-phase testing activities.
​
Vadim holds a Master of Science in Chemical Engineering from Georgian Technical University in the Republic of Georgia and an MBA in International Business from Lincoln University in San Francisco, California. His international leadership experience includes pivotal roles at Genentech Singapore, where he was instrumental in launching drug substance manufacturing facilities and QC laboratories, and at Roche in Basel, Switzerland, where he led global quality projects across multiple countries.
“I am thrilled to join GeneFab and look forward to working with the talented team to enhance the quality framework necessary to support our ambitious growth plans,” said Vadim Eristavi. “Together, we will build on GeneFab's strong foundation to ensure that our operations meet the highest standards of regulatory compliance and operational excellence.”
​
GeneFab is committed to delivering exceptional value and quality in the rapidly evolving cell and gene therapy landscape. With Vadim’s leadership in quality, the company is poised to advance its mission of providing top-tier services to its partners and clients.
About GeneFab
GeneFab is a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With a focus on innovation, quality, and logistical excellence, GeneFab partners with biopharmaceutical companies to accelerate the development and commercialization of life-changing therapies.
​
​For further information or media inquiries, please contact Eric Blair at eric.blair@genefab.com.